Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Accumulated Expenses (2022 - 2025)

Oramed Pharmaceuticals' Other Accumulated Expenses history spans 4 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, changed N/A, while the annual FY2025 figure was $1.7 million, N/A changed from the prior year.
  • Other Accumulated Expenses reached $1.7 million in Q4 2025 per ORMP's latest filing, up from $59000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q4 2025 to a low of $5000.0 in Q4 2022.
  • Average Other Accumulated Expenses over 4 years is $255700.0, with a median of $96000.0 recorded in 2023.
  • The largest YoY upside for Other Accumulated Expenses was 1080.0% in 2023 against a maximum downside of 55.64% in 2023.
  • A 4-year view of Other Accumulated Expenses shows it stood at $5000.0 in 2022, then skyrocketed by 1080.0% to $59000.0 in 2023, then changed by 0.0% to $59000.0 in 2024, then surged by 2801.69% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other Accumulated Expenses are $1.7 million (Q4 2025), $59000.0 (Q1 2024), and $59000.0 (Q4 2023).